Warning Letter: Nephron Pharmaceuticals - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Warning Letter: Nephron Pharmaceuticals

ePT--the Electronic Newsletter of Pharmaceutical Technology

On Dec. 20, the US Food and Drug Administration posted a Warning Letter issued Sept. 28 to Nephron Pharmaceuticals Corp. (Orlando, FL, www.nephronpharm.com) by the agency's Florida District Office (Maitland, FL).

The warning cited the respiratory-therapy company for failing to adequately report postmarketing adverse drug experiences (PADEs) and for lapses in current good manufacturing practice (CGMP) in the production of albuterol sulfate inhalation solution, ipratropium bromide inhalation solution, racepinephrine inhalation solution, and sodium chloride inhalation solution.

The cited CGMP deficiencies included: lack of written provisions for reviewing complaints; failure to investigate batch failures or discrepancies; failure to establish process controls for identity, strength, and purity; deviations from established specifications without justification;, and lack of calibration and inspection records for manufacturing equipment.

FDA's warning letter did indicate that the company's May 25 response "appears to be adequate," but also said, "we are concerned that your firm may not fully understand the role of the quality control unit in your overall manufacturing process."

-Douglas McCormick


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here